Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Beauty Health (SKIN) EBITDA (2020 - 2025)

Beauty Health (SKIN) has disclosed EBITDA for 6 consecutive years, with -$10.6 million as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA rose 37.97% to -$10.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$9.8 million, a 63.38% increase, with the full-year FY2024 number at -$33.0 million, up 66.52% from a year prior.
  • EBITDA was -$10.6 million for Q3 2025 at Beauty Health, down from $23.3 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $31.3 million in Q1 2022 to a low of -$139.7 million in Q2 2021.
  • A 5-year average of -$13.5 million and a median of -$5.5 million in 2021 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: soared 5298.24% in 2022, then tumbled 4262.9% in 2023.
  • Beauty Health's EBITDA stood at -$20.6 million in 2021, then soared by 128.33% to $5.8 million in 2022, then plummeted by 225.42% to -$7.3 million in 2023, then crashed by 84.97% to -$13.6 million in 2024, then increased by 21.82% to -$10.6 million in 2025.
  • Per Business Quant, the three most recent readings for SKIN's EBITDA are -$10.6 million (Q3 2025), $23.3 million (Q2 2025), and -$9.0 million (Q1 2025).